β2-adrenoreceptor Inverse Agonist Down-regulates Muscarine Cholinergic Subtype-3 Receptor and Its Downstream Signal Pathways in Airway Smooth Muscle Cells in vitro
- PMID: 28051147
- PMCID: PMC5209700
- DOI: 10.1038/srep39905
β2-adrenoreceptor Inverse Agonist Down-regulates Muscarine Cholinergic Subtype-3 Receptor and Its Downstream Signal Pathways in Airway Smooth Muscle Cells in vitro
Retraction in
-
Retraction Note: β2-adrenoreceptor Inverse Agonist Down-regulates Muscarine Cholinergic Subtype-3 Receptor and Its Downstream Signal Pathways in Airway Smooth Muscle Cells in vitro.Sci Rep. 2019 Mar 6;9(1):4109. doi: 10.1038/s41598-019-39065-w. Sci Rep. 2019. PMID: 30842524 Free PMC article.
Abstract
Mechanisms underlying β2-adrenoreceptor (β2AR) inverse agonist mediated bronchoprotectiveness remain unknown. We incubated ICI118,551, formoterol, budesonide, and formoterol plus budesonide, as well as ICI118,551 or pindolol plus formoterol, ICI118,551 plus forskolin, SQ22,536 or H89 plus formoterol in ASMCs to detect expressions of M3R, PLCβ1 and IP3. The level of M3R in the presence of 10-5 mmol/L ICI118,551 were significantly decreased at 12 h, 24 h and 48 h (P < 0.05), and at 24 h were significantly reduced in ICI118,551 with concentration of 10-5 mmol/L, 10-6 mmol/L, 10-7 mmol/L, and 10-8 mmol/L (P < 0.05). The level of IP3 in 10-5 mmol/L ICI118,551 was significantly diminished at 24 h (P < 0.01), except for that at 1 h, neither was in the level of PLCβ1. A concentration of 10-5 mmol/L ICI118,551 at 24 h showed a significant reduction of M3R level compared to formoterol (P < 0.01), budesonide (P < 0.01), and formoterol + budesonide (P < 0.05), but significant reduction of PLCβ1 and IP3 was only found between 10-5 mmol/L ICI118,551 and formoterol at 24 h, but not in the comparison of budesonide or formoterol + budesonide. Pindolol and H89 could not inhibit the formoterol-induced expression of M3R (P > 0.05), but SQ22,536 significantly antagonized the formoterol-induced M3R expression (P < 0.05). In conclusions, β2AR inverse agonist, ICI118,551, exerts similar bronchoprotective effects to corticosteroids via decreasing the expression of M3R and inhibiting the production of IP3.
Figures







Similar articles
-
A long-acting β2-adrenergic agonist increases the expression of muscarine cholinergic subtype‑3 receptors by activating the β2-adrenoceptor cyclic adenosine monophosphate signaling pathway in airway smooth muscle cells.Mol Med Rep. 2015 Jun;11(6):4121-8. doi: 10.3892/mmr.2015.3307. Epub 2015 Feb 5. Mol Med Rep. 2015. PMID: 25672589 Free PMC article.
-
β2-Agonists upregulate PDE4 mRNA but not protein or activity in human airway smooth muscle cells from asthmatic and nonasthmatic volunteers.Am J Physiol Lung Cell Mol Physiol. 2012 Feb 1;302(3):L334-42. doi: 10.1152/ajplung.00163.2011. Epub 2011 Nov 18. Am J Physiol Lung Cell Mol Physiol. 2012. PMID: 22101762
-
Budesonide enhances agonist-induced bronchodilation in human small airways by increasing cAMP production in airway smooth muscle.Am J Physiol Lung Cell Mol Physiol. 2020 Feb 1;318(2):L345-L355. doi: 10.1152/ajplung.00393.2019. Epub 2019 Nov 20. Am J Physiol Lung Cell Mol Physiol. 2020. PMID: 31747297 Free PMC article.
-
Achieving asthma control with ICS/LABA: A review of strategies for asthma management and prevention.Respir Med. 2016 Feb;111:1-7. doi: 10.1016/j.rmed.2015.11.002. Epub 2015 Nov 6. Respir Med. 2016. PMID: 26614594 Review.
-
Budesonide/formoterol pressurized metered-dose inhaler for patients with persistent asthma.Allergy Asthma Proc. 2010 May-Jun;31(3):190-202. doi: 10.2500/aap.2010.31.3356. Allergy Asthma Proc. 2010. PMID: 20482961 Review.
References
-
- Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). (2012). Available at: www.ginasthma.org. (Accessed: 13rd March 2012).
-
- U.S. Food & Drug Administration. FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs). (2010). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa... (Accessed: 18rd February 2010).
-
- Rich M. W. et al.. A randomized comparison of intravenous amrinone versus dobutamine in older patients with decompensated congestive heart failure. J Am Geriatr Soc 43, 271–274 (1995). - PubMed
-
- O’Connor C. M. et al.. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138, 78–86 (1999). - PubMed
-
- Packer M. et al.. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334, 1349–1355 (1996). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials